Cancer/Testis Antigen Expression on Mesenchymal Stem Cells Isolated from Different Tissues

The expression of cancer/testis antigens (CTAs) on additional normal tissues or stem cells may restrict their use as cancer targets. The objective of the present study was to evaluate the mRNA levels of some CTAs in a variety of tissues. mRNA of pericytes, fibroblasts and mesenchymal stem cells (MSC...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2010-12, Vol.30 (12), p.5023-5027
Main Authors: SALDANHA-ARAUJO, Felipe, HADDAD, Rodrigo, LUCIOLA ZANETTE, Dalila, GOES DE ARAUJO, Amélia, DELGADO ORELLANA, Maristela, TADEU COVAS, Dimas, ZAGO, Marco Antonio, PANEPUCCI, Rodrigo Alexandre
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - biosynthesis
Biological and medical sciences
Fibroblasts - immunology
Humans
Immunophenotyping
Medical sciences
Melanoma-Specific Antigens
Membrane Proteins - biosynthesis
Mesenchymal Stromal Cells - immunology
Neoplasm Proteins - biosynthesis
Pericytes - immunology
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The expression of cancer/testis antigens (CTAs) on additional normal tissues or stem cells may restrict their use as cancer targets. The objective of the present study was to evaluate the mRNA levels of some CTAs in a variety of tissues. mRNA of pericytes, fibroblasts and mesenchymal stem cells (MSCs) derived from adult and fetal tissues, human umbilical vein endothelial cells, MSC-derived adipocytes, selected normal tissues and control cancer cell lines (CLs) were extracted and quantitative polymerase chain reaction was performed for MAGED1, PRAME, CTAG1B, MAGEA3 and MAGEA4. MAGED1 was expressed in all normal tissues and cells evaluated. CTAG1B was expressed at levels comparable to control CLs on MSCs derived from arterial, fetal skin, adipose tissue and saphenous vein, heart, brain and skin tissues. MAGEA4 was detected only in fibroblasts and differentiated adipocytes from MSCs, at levels comparable to the control CLs. The potential use of CTAs in immunotherapy should take into account the potential off-target effects on MSCs.
ISSN:0250-7005
1791-7530